In preclinical studies, metformin has been shown to inhibit the viability of imatinib-resistant CML cells (K562R) and BCR-ABL-mutant CML cells, induce apoptosis, and downregulate the mTORC1 signaling pathway [82]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.